To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

CompletedOBSERVATIONAL

Enrollment

2,150

Participants

Timeline

Start Date

December 14, 2015

Primary Completion Date

September 25, 2017

Study Completion Date

January 26, 2018

Conditions

Wet Macular Degeneration

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.

Trial Locations (1)

Multiple Locations